Bausch Health Companies Inc. (BHC)
NYSE: BHC · Real-Time Price · USD
8.19
0.00 (0.00%)
Nov 20, 2024, 4:00 PM EST - Market closed
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $2.51B in the quarter ending September 30, 2024, with 12.15% growth. This brings the company's revenue in the last twelve months to $9.47B, up 10.91% year-over-year. In the year 2023, Bausch Health Companies had annual revenue of $8.76B with 7.79% growth.
Revenue (ttm)
$9.47B
Revenue Growth
+10.91%
P/S Ratio
0.32
Revenue / Employee
$467,390
Employees
20,270
Market Cap
3.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
| Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
| Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
| Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
| Dec 31, 2019 | 8.60B | 221.00M | 2.64% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 10.59B |
| Acadia Healthcare Company | 3.12B |
| Neogen | 912.20M |
| PTC Therapeutics | 900.66M |
| Apellis Pharmaceuticals | 715.22M |
| Inari Medical | 574.50M |
| Merus | 35.93M |
| Agios Pharmaceuticals | 32.87M |
BHC News
- 2 days ago - US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug - Reuters
- 3 days ago - PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS - Accesswire
- 3 days ago - Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis - Accesswire
- 7 days ago - Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs - Business Wire
- 21 days ago - Bausch Health Companies, Inc. (BHC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Bausch Health Announces Third Quarter 2024 Results - Accesswire
- 22 days ago - Bausch + Lomb Announces Third-Quarter 2024 Results - Business Wire
- 24 days ago - ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence - Accesswire